Merck's Keytruda, or pembrolizumab, has been approved by the FDA as an adjuvant therapy for patients with melanoma who have lymph node involvement after complete resection. The approval is the 17th indication of the drug in the US.
Sign up for SNMMI SmartBrief
Nuclear medicine and molecular imaging news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.